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While allelic losses and mutations of tumor suppressor genes implicated in the etiology of astrocytoma have been widely assessed,
the role of epigenetics is still a matter of study. We analyzed the frequency of promoter hypermethylation by methylation-specific
PCR (MSP) in five tumor suppressor genes (PTEN, MGMT, RASSF1A, p14ARF, and p16INK4A), in astrocytoma samples and cell
lines. RASSF1A was the most frequently hypermethylated gene in all grades of astrocytoma samples, in cell lines, and in adult
secondary GBM. It was followed by MGMT. PTEN showed a slight methylation signal in only one GBM and one pilocytic astro-
cytoma, and in two cell lines; while p14ARF and p16INK4A did not show any evidence of methylation in primary tumors or cell
lines. In pediatric GBM, RASSF1A was again the most frequently altered gene, followed by MGMT; PTEN, p14 and p16 show-
ed no alterations. Lack or reduced expression of RASSF1A in cell lines was correlated with the presence of methylation. RASSF1A
promoter hypermethylation might be used as a diagnostic marker for secondary GBM and pediatric GBM. Promoter hyper-
methylation might not be an important inactivation mechanism in other genes like PTEN, p14ARF and p16INK4A, in which other
alterations (mutations, homozygous deletions) are prevalent.
1. Introduction
The role of epigenetics in the control of gene expression is
having an increasing interest in cancer research. Aberrant
cytosine methylation can promote tumor initiation or pro-
gression, both by excess (promoter hypermethylation of tu-
mor suppressor genes) and defect (global genome hypo-
methylation, which can lead to chromosomal instability, re-
activation of parasitic sequences, and loss of genomic im-
printing).
In the last decade, several authors have reported the im-
portance of epigenetic silencing of tumor suppressor genes
in a wide range of human tumors. Some of these tumor sup-
pressor genes inactivated by cytosine methylation on their
promoters are p14ARF, APC, MLH1, and MGMT in colon
cancer [1], DAPK in bladder superficial carcinoma [2],
CDKN2B in leukemia and lymphoma [1], GSTP1 in prostate
cancer and hepatocarcinoma [3], Caspase-8 in neuroblas-
toma [4], and RASSF1A in medulloblastoma, Wilms’ tumor,
and neuroblastoma [5]. Some of the main functions of
these genes aﬀect cell cycle control (CDKN2B, p14ARF), DNA
damage repairing (MGMT, MLH1), cell adhesion (APC),
apoptotic response (Caspase-8, DAPK), and microtubule
stability (RASSF1A).
To date, chromosomal gains (+7) and losses (−10), allel-
ic losses (10q, 9p), oncogene amplifications (MDM2, CDK4,
EGF), and homozygous deletions and mutations of tumor
suppressor genes (CDKN2A, TP53, PTEN, RB1, DMBT1)
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have been the most frequently found alterations in astro-
cytoma. However, methylation has been studied in a much
lesser extent in astrocytic tumors. Recently, MGMT pro-
moter hypermethylation has been associated to secondary
glioblastoma phenotype and to an increase in GC→AT mu-
tations in TP53 gene [6]. But promoter hypermethylation of
other putative tumor suppressor genes has been less studied
in astrocytomas, where LOH and mutational analysis have
been prevalent.
PTEN, in 10q23.3, which has been demonstrated as a
critical tumor suppressor gene frequently mutated in high-
grade astrocytomas, has also been reported to be inactivated
by methylation-dependent mechanisms in NSCLC [7] and
carcinomas of the endometrium [8] and prostate [9].
Mutations on its coding region have been described in 30%
high-grade astrocytomas, mainly in primary glioblastomas
[10]. However, this mutation rate does not correlate with the
higher frequency of LOH at 10q, which reaches 80–90% in
both primary and secondary glioblastomas [11, 12]. Some
authors then propose that (a) PTEN might be inactivated in
high-grade astrocytomas by diﬀerent mechanisms to LOH
and mutations (e.g., promoter hypermethylation) and (b)
other tumor suppressor genes might map 10q, near the
PTEN locus.
Two important tumor suppressor loci map 9p21:
CDKN2B (p15INK4B) and CDKN2A, which code for two
alternative protein products, p14ARF and p16INK4A. These
three protein products negatively regulate cell cycle progres-
sion: p15 and p16INK4A act in the CDK/cyclin/Rb pathway,
while p14ARF participates in the p14/MDM2/p53/p21 route.
So, homozygous deletion of CDKN2A locus alters cell cycle
regulation in two diﬀerent but synergistic variants: p53 and
Rb pathways. CDKN2A has a high frequency of homozygous
deletions in high-grade astrocytomas, while mutations and
promoter methylation of p14ARF or p16INK4A have a lesser
importance in these tumors [13, 14].
Finally, recent reports have pointed at the RASSF1A gene,
on 3p21.3 [15], as an important tumor suppressor gene in-
activated in several neoplasms, such as NSCLC, melanoma,
breast, kidney, bladder, and prostate cancer and in some
pediatric tumors, like medulloblastoma, neuroblastoma, and
Wilms’ tumor [5]. RASSF1A is a Ras eﬀector, whose function
was thought to mediate the Ras apoptotic response; however,
recent reports have demonstrated how RASSF1A is involved
in maintaining cytoskeletal integrity [16] and regulating mi-
tosis [17]. While mutations and homozygous deletions of
its coding region are rare, promoter hypermethylation is the
main cause of RASSF1A inactivation in cancer [15]. The pos-
sibility that alterations of RASSF1A may participate in the
etiology of astrocytic tumors has not been much studied to
date.
Our aim was to study the promoter methylation status
of these five important tumor suppressor genes (p14ARF,
p16INK4A, MGMT, PTEN, and RASSF1A), in a subset of as-
trocytomas and cell lines. While the methylation frequency
of some of them (p14ARF, p16INK4A, and MGMT) has been
widely assessed in high-grade astrocytomas, it has not been
much studied in low-grade astrocytic tumors. Moreover,
promoter hypermethylation as an inactivation mechanism of
PTEN and RASSF1A genes has rarely been studied in astro-
cytomas.
2. Material andMethods
2.1. Tumor Specimens. A total number of 61 astrocytic tu-
mors were analyzed byMSP; 23 were obtained from the Gen-
eral Hospital of the Medical University of Tianjin, Tianjin,
China: 8 GBM, 6 AIII, and 9 AII; 26 were obtained from the
Hospital de Navarra, Pamplona, Spain: 19 adult GBM, 2 AII,
4 AI, and 1 pediatric GBM. All these tumors had been frozen
in liquid nitrogen after surgical extraction. Finally, 12 cases of
high-grade pediatric astrocytomas included in paraﬃn were
obtained from the Hospital Miguel Servet, Zaragoza, Spain.
2.2. Cell Lines. Astrocytoma cell lines U87 MG, T98G
(grade IV), and MOG-G-CCM (grade III) were purchased
from the European Collection of Cell Cultures (ECACC,
Salisbury, UK); cell lines U251, U118 (grade IV astrocyto-
mas), SW1783, and SW1088 (grade III astrocytomas) were
purchased from the American Type Culture Collection
(ATCC, Manassas, VA); finally, cell lines LN-405 (grade IV
astrocytoma) and GOS3 (grade II/III astrocytoma/oligoden-
droglioma) were obtained from the Deustche Sammlung
von Mikroorganismen und Zellkulturen GmbH (DSMZ,
Braunchsweig, Germany). Cell lines were grown in RPMI
supplemented with 10% FBS, 1% penicillin/streptomycin,
and 5% MEM nonessential aminoacids. Medium was re-
stored three times a week, and subcultures were done before
cells reached confluence.
2.3. Nucleic Acids Extraction. DNA was obtained with phe-
nol-chloroform purification from the frozen tissues. Paraﬃn
embedded samples were taken into a series of alcohol in
decreasing grade and, then, left until they were totally dried.
Tissues were resuspended in 1mL lysis solution buﬀer (0.5M
NaCl; 50mM Tris-HCl, pH 7.6; 50mM EDTA; 0.5% SDS)
and were incubated with 20 μL proteinase K (20mg/mL)
at 56◦C, overnight. After that, 0.4mL saturated NaCl were
added to the mixture, shaked, and spun at 13.000 rpm,
10min. Supernatant was carried to a new tube, and DNA
was precipitated by adding 2 volumes of absolute ethanol at
−80◦C. The DNA was washed twice in 70% ethanol, dried,
and resuspended in 200–500 μL Tris-EDTA Buﬀer (10mM
Tris-HCl, 1mM EDTA, pH 7.6).
RNA from cell lines was extracted with TRIzol Reagent
(Invitrogen Ltd., Paisley, UK), following manufacturers’ in-
structions.
2.4. Sodium Bisulfite Modification. Sodium bisulfite DNA
modification was done as previously described [18]. One
μg DNA was mixed with 10 μg Herry Sperm’s DNA and
1,7 μL 6M NaOH to a final volume of 50 μL and denatured
at 37–42◦C, 15min. Then, 30 μL 100mM hydroquinone
and 520 μL 3M sodium bisulfite pH 5.0 were added, and
the reactions were incubated at 56◦C for 16 h. To avoid
liquid evaporation, eight drops of mineral oil were added
to the mixture. Modified DNAs were recovered and purified
by using the Wizard DNA Clean-Up System (Promega,
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Table 1: Primers and conditions for PCRs.
Gene Primer sense Primer antisense Size
T
(◦C)
Cycles
PTEN
-Methylation
-U 5′-GTGTTGGTGGAGGTAGTTGTTT-3′ 5′-ACCACTTAACTCTAAACCACAACCA-3′ 162 bp 62◦C 38
-M 5′-TTCGTTCGTCGTCGTCGTATTT-3′ 5′-GCCGCTTAACTCTAAACCGCAACCG-3′ 206 bp 62◦C 38
MGMT
-Methylation
-U
5′-GAGAGATTTGTGTTTTGGGTTTAGTG-
3′
5′-CCTTCAACCAATACAAACCAAACAA-3′ 236 bp 62◦C 38
-M 5′-ATTCGCGTTTCGGGTTTAGC-3′ 5′-CGACCGATACAAACCGAACG-3′ 227 bp 62◦C 38
-Expression 5′-GGGGAAGCTGGAGCTGTCTG-3′ 5′-TCTCCGAATTTCACAACCTTCA-3′ 282 bp 62◦C 32
RASSF1A
-Methylation
-U 5′-GAGAGTGTGTTTAGTTTTGTTTTTG-3′ 5′-CCCATACTTCACTAACTTTAAACAC-3′ 183 bp 56◦C 38
-M 5′-GAGAGCGCGTTTAGTTTCGTTTTC-3′ 5′-ACCCGTACTTCGCTAACTTTAAACG-3′ 184 bp 62◦C 35
-Expression 5′-TCTGTGGCGACTTCATCTGG-3′ 5′-TTGGGCAGGTAAAAGGAAGT-3′ 424 bp 60◦C 35
p14ARF
-Methylation
-U
5′-TTTTTGGTGTTAAAGGGTGGTGTAGT-
3′
5′-CACAAAAACCCTCACTCACAACAA-3′ 132 bp 62◦C 35
-M 5′-GTGTTAAAGGGCGGCGTAGC-3′ 5′-AAAACCCTCACTCGCGACGA-3′ 122 bp 58◦C 35
-Expression 5′-CCGCCGCGAGTGAGGGTTTT-3′ 5′-GCACGGGTCGGGTGAGAGTGG-3′ 242 bp 65◦C 32
P16INK4A
-Methylation
-U 5′-TTATTAGAGGGTGGGGTGGATTGT-3′ 5′-CAACCCCAAACCACAACCATAA-3′ 150 bp 62◦C 35
-M 5′-TTATTAGAGGGTGGGGCGGATCGC-3′ 5′-GACCCCGAACCGCGACCGTAA-3′ 151 bp 65◦C 35
-Expression 5′-CGCGCGTACAGATCTCTCGAA-3′ 5′-CACGGGTCGGGTGAGAGTGG-3′ 161 bp 68◦C 35
TFR
-Expression 5′-GTCAATGTCCCAAACGTCACCAGA-3′ 5′-ATTTCGGGAATGCTGAGAAAACAGACAGA-3′ 298 bp 60◦C 30
U: unmethylated; M: methylated.
Madison, WI), according to the manufacturer and eluted in
30–50 μL Tris-EDTA Buﬀer (10mM Tris-HCl, 1mM EDTA,
pH 7.6). These elutions were stored at −20◦C until their use.
2.5. MSP. 1.5–2.5 μL modified DNA were used as template
for each methylation-specific PCR. DNAs were added to
mixes which contained 0.8mM dNTPs, 2-3mM MgCl2,
2.5 μL 10X reaction buﬀer, 5–15 pmol primers, 5% μL
DMSO, and 1U AmpliTaq Gold DNA polymerase (Applied
Biosystems, Foster City, CA). For p14ARF and p16INK4A,
amplification BioTaq DNA polymerase (Bioline Ltd., Lon-
don, UK) was used, in a final volume reaction of 50 μL. Five
μL 0.1M β-mercaptoethanol were added to the PCR mix
for p14ARF amplification. Primers for MGMT and RASSF1A
amplification were designed by using MethPrimer software
[19] and are listed in Table 1. Primers for PTEN, p14ARF, and
p16INK4A (Table 1) had been previously described [8, 18].
2.6. RT-PCR. Five μg RNA from each cell line were mixed
with 2 μL dNTPs, 20mM, and 2 μL random primers 250 μM
in a final volume of 10 μL. The mixture was heated at 65◦C,
10min, and then 4 μL 5X Reaction Buﬀer, 2 μL 0.1mMDTT,
and 1U RNAse Out (Invitrogen Life Technologies, Carlsbad,
CA) were added. The mixture was heated at 42◦C for 2min
and incubated with 1U Superscript II RNA Retrotranscrip-
tase (Invitrogen Life Technologies, Carlsbad, CA). Samples
were heated at 42◦C for 50min, and a final step at 72◦C
for 10min was used. cDNAs were diluted 1 : 5 and stored at
−20◦C until their use.
RT-PCR conditions for studying PTEN expression had
been previously described [20]. For p14ARF, p16INK4A,
MGMT, and RASSF1A expression, 1.5–2.0 μL 1 : 5 diluted
cDNA were used as template for each RT-PCR. cDNAs were
added to a mixture that contained 0.8mM dNTPs, 2.5 μL
10X Reaction Buﬀer, 1.5mM MgCl2, 5 pmol primers, and
1U AmpliTaq Gold DNA polymerase (Applied Biosystems,
Foster City, CA), in a final volume of 25 μL. Primers were
designed with Oligo 4.0 software (NBI, Hamel, MN) and are
depicted in Table 1. An RT-PCR of the transferrin receptor
gene (TFR) was done as internal control of the RNA amount.
4 ISRN Neurology
Table 2: Promoter hypermethylation and expression in cell lines.
Cell line Diagnosis Methylation Expression
PTEN MGMT RASSF1A p14 p16 PTEN MGMT RASSF1A p14 p16
T98G GBM −   − ∗ + + − − −
LN-405 GBM −   − − + − −/+ + +
U118 GBM −   ∗ ∗ § § § § §
U251 GBM −   ∗ ∗ § § § § §
U87 GBM −   ∗ ∗ + − − − −
MOG-G-CCM AIII    − ∗ + + − + +
SW1088 AIII −   ∗ ∗ − − −/+ − −
SW1783 AIII − −  − − + + − + +
GOS3 A/O (II/III)  −  ∗ − + − − − −
GBM: glioblastoma multiforme; AIII: anaplastic astrocytoma; A/O: astrocytoma/oligodendroglioma. : methylated; : hemimethylated; +: expression; −/+:
low expression; −: lack of expression/absence of methylation; ∗: nonanalyzed; §: nonstudied.
3. Results
3.1. Adult Astrocytomas
3.1.1. p14ARF and p16INK4A. Just 34 and 44 of the 48 adult as-
trocytomas could be assessed for p14ARF and p16INK4A pro-
moter hypermethylation, respectively. We could not find any
evidence of methylation in all samples tested (Figure 1).
p14ARF hypermethylation could be studied in four astro-
cytoma cell lines (T98G, LN405, SW1783, and MOG-G-
CCM), without finding any case of methylation (Table 2).
p16INK4A was studied in three cell lines (LN405, SW1783,
and GOS3) without detecting any alteration. Cell lines
U87MG, U118 MG, SW1088, and U251 MG did not show
any interpretable band either for p14ARF or for p16INK4A
methylation-specific PCR.
3.1.2. PTEN. PTEN promoter status was analyzed in a total
number of 43 adult astrocytomas (Figure 1). We could
only find two cases of methylation: a primary glioblastoma
(HN16), which represented 4% of all glioblastomas tested,
and 1 pilocytic astrocytoma (HN21), which showed a slight
signal of methylation.
We could study all cell lines and found two cases with
methylation in one PTEN allele (cell lines GOS3 and MOG-
G-CCM) (Figure 2(c), Table 2).
3.1.3. MGMT. MGMT could be studied in 48 astrocytoma
cases, and alterations were found in all grades but in pilocytic
astrocytomas (Figure 1). Six glioblastomas (24%), 3 diﬀuse
astrocytomas (30%), and 1 anaplastic astrocytoma (17%)
showed MGMT promoter hypermethylation (Figure 2(a)).
This gene also showed promoter hypermethylation in 7
of 8 astrocytoma cell lines analyzed (Figure 2(b), Table 2).
U87MG cells could not be evaluated.
3.1.4. RASSF1A. RASSF1A could be analyzed in 44 adult
astrocytic tumors. This gene showed the highest frequency
of hypermethylation in all grades studied, with the exception
of pilocytic astrocytomas (Figure 1). Eight glioblastomas
(33%), 2 anaplastic astrocytomas (33%), and 4 low-grade
diﬀuse astrocytomas (40%) were hypermethylated for
this gene (Figure 2(a)). We saw an statistically significant
association between secondary glioblastoma phenotype
and RASSF1A promoter methylation, as 4 of 5 tumors
studied showed methylation of this gene; however, in the
primary glioblastoma group, we could just detect 4 cases of
methylation in 19 cases analyzed (Fisher’s exact test, P =
0, 028) (Figure 3). All cell lines showed RASSF1A methyla-
tion (Table 2).
3.2. Pediatric Astrocytomas. Thirteen high-grade pediatric
astrocytomas were studied for methylation in the five genes
(Figure 1). RASSF1A was the most frequently altered gene in
this group, with 4 of 9 cases analyzed showing methylation
(44%) (Figure 2(b)). MGMT showed promoter hypermethy-
lation in 1 case of 6 studied (17%), while neither PTEN,
p14ARF, or p16INK4A showed methylation in any sample.
3.3. RT-PCR. We studied expression of both five genes in all
astrocytoma and neuroblastoma cell lines by an RT-PCR ap-
proach (Table 2). Expression could not be evaluated in
U118MG and U251 cells, as RNA was not available.
3.3.1. RASSF1A. RASSF1A was the most frequently altered
gene and lacked expression in all cell lines (Figure 4).
3.3.2. PTEN. Astrocytoma cell line SW1088 lacked PTEN ex-
pression (not shown); however, this lack was not due to pro-
moter hypermethylation, but to a homozygous deletion
encompassing this gene (data not shown). Cell lines GOS3
and MOG-G-CCM, both presenting methylation in one
PTEN allele, did not show a significant loss of expression
when compared with other cell lines and a control with nor-
mal human astrocytes (NHA, Cambrex, East Rutherford,
NJ).
3.3.3. MGMT. Cell lines LN405, SW1088, and U87MG,
which suﬀered MGMT promoter methylation, also showed
lack of expression of this gene; on the contrary, SW1783 cells
did not have MGMT hypermethylation and expressed the
gene (Figure 4). We did not find correlation betweenMGMT
ISRN Neurology 5
HN11
HN13
HN15
HN16
HN19
HN31
HN36
HN43
HN49
HN51
HN53
HN54
HN79
HN89
G7
G8
G9
G16
G20
G24
G28
G33
HN20
HN35
HN84
HN91
HN93
Secondary GBM
Primary GBM
Pediatric GBM
HN1
T36
T37
T38
T39
T40
T41
T43
T44
T45
T46
T48
T49
A37
A41
A42
A43
A44
A45
AIII
AII
AI
HN21
HN26
HN62
TG109
HN14
HN70
A47
A48
A49
A55
A56
A57
A58
A59
A60
P
T
E
N
R
A
SS
F1
A
M
G
M
T
p1
4
p1
6
P
T
E
N
R
A
SS
F1
A
M
G
M
T
p1
4
p1
6
P
T
E
N
R
A
SS
F1
A
M
G
M
T
p1
4
p1
6
Figure 1: Methylation of PTEN, MGMT, RASSF1A, p16INK4A, and p14ARF in adult and pediatric astrocytomas. Black boxes: presence of
methylation; white boxes: absence of methylation; gray boxes: notdetermined. GBM: glioblastoma multiforme; AIII: anaplastic astrocytoma;
AII: low-grade diﬀuse astrocytoma; AI: pilocytic astrocytoma.
methylation and lack of expression in cell lines MOG-G-
CCM and T98G: both were methylated and expressed the
gene.
3.3.4. p14ARF and p16INK4A. LN405, MOG-G-CCM, and
SW1783 astrocytoma cells expressed p14ARF, while T98G,
U87MG, GOS3, and SW1088 did not (Figure 4). A meth-
ylation-specific PCR approach could just be done for T98G,
MOG-G-CCM, LN405, and SW1783, without finding any
case of methylation. So, lack of expression in T98G cells
seems not to be methylation-related.
In the case of p16INK4A expression, just LN405, MOG-
G-CCM, and SW1783 cells showed expression, while T98G,
GOS3, SW1088, and U87MG did not (Figure 4). For this
gene, only LN405, SW1783, and GOS3 could be evaluated by
an MSP approach, without finding any evidence for meth-
ylation.
4. Discussion
In spite of the pivotal role of aberrant methylation described
in other tumors [1], few are the studies which analyze pro-
moter methylation of tumor suppressor genes in astrocy-
toma. However, methylation of some genes, like MGMT,
has demonstrated to be critical, not only in tumorigenesis,
but also in astrocytoma drug resistance [6, 21]. A recent re-
port has found an increase of promoter hypermethylation in
CALCA and CDH1 genes in high-grade astrocytomas, but
they did not see any remarkable methylation frequency of
other classical tumor suppressor genes, such as p14ARF, RB1,
CDKN2B, or APC [22].
Baeza et al. [23] reported a methylation frequency of
35% for PTEN in high-grade astrocytomas and in 4 of 11
astrocytoma cell lines. They suggested that PTEN could also
be inactivated by aberrant promoter methylation in glioblas-
tomas, giving an explanation for the relatively low frequency
of PTEN mutations discovered to date in these tumors. In
our hands, however, PTEN promoter was not altered in the
majority of glioblastomas analyzed, as only one of 25 cases
studied presented a slight signal of methylation (4%). We
could not find PTEN methylation either in high-grade or
in low-grade astrocytomas, except one case of pilocytic as-
trocytoma, which showed a faint methylation signal. We con-
sider this discrepancy unlikely to be due to diﬀerent sample
sizes, as we analyzed a total amount of 43 adult astrocytic
tumors (25 GBM, 5 AIII, 9 AII, and 4 AI). It cannot be
due to the fact that we analyzed another sequence in the
CpG island of PTEN, as they also used two sets of primers
including ours and obtained the same results. However, we
could not reproduce our results when using their primers set
(data not shown). Probably these diﬀerences are due to racial
disparities or to the diﬀerent geographic origin of individuals
in both studies.
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Figure 2: (a) MGMT and RASSF1A promoter hypermethylation in astrocytomas determined by MSP. PCR products were run in a 2%
agarose gel stained with 0.5 μg/mL ethidium bromide. B16: DNA obtained from blood of a normal donor; HN26: pilocytic astrocytoma;
HN35: secondary glioblastoma; HN36: primary glioblastoma. m: 1 Kb plus DNA marker; U: unmethylated; M: methylated. C+: DNA
methylated with Sss I (CpGenome, Intergen, Edimburgh, UK), positive control for methylation; C−: water. (b) RASSF1A, PTEN, and
MGMT promoter hypermethylation in pediatric high-grade astrocytomas determined by MSP. PCR products were run in a 2% agarose
gel stained with 0.5 μg/mL ethidium bromide. B27: DNA obtained from blood of a normal donor; T36–T49: DNA from paraﬃn-
embedded pediatric astrocytomas; SW48: colorectal cancer cell line with MGMT promoter hypermethylation, used as a positive control
for DNA methylation; C+: Sss I methylated DNA (CpGenome, Intergen, Edimburgh, UK), used as a positive control for methylation; U:
unmethylated; M: methylated. (c) PTEN, MGMT, and RASSF1A promoter hypermethylation in astrocytoma cell lines determined by MSP.
PCR products were visualized in a 2% agarose gel stained with 0.5 μg/mL ethidium bromide. B23: DNA from blood of a normal donor;
GOS3: astrocytoma/oligodendroglioma cell line (grades II/III); U251: glioblastoma multiforme; U118: glioblastoma multiforme; SW1088:
anaplastic astrocytoma; SW1783: anaplastic astrocytoma; T98G: glioblastoma multiforme; C+: DNA methylated with Sss I (CpGenome,
Intergen, Edimburgh, UK), positive control for methylation; C−: water. Neuroblastoma cell lines Kelly, MC-IXC, Be(2)C, and MHH-NB-11
were included in the study. m: molecular weight DNA marker, 1 Kb Plus DNA ladder (Invitrogen, Life and Technologies, Carlsbad, CA); U:
unmethylated; M: methylated. Some other cell lines, diﬀerent to astrocytoma, appear in the figure.
We did not find any case with p14ARF or p16INK4A pro-
moter hypermethylation, either in high- and low-grade tu-
mors or in pediatric astrocytic tumors. Homozygous dele-
tion has been described as the major inactivating mechanism
for the CDKN2A products [14], while several authors have
found promoter methylation of p14ARF and/or p16INK4A in a
subset of astrocytic tumors [24]. However, this frequency is
quite low as compared with homozygous deletions. Several
publications fail to find or just find a very low rate of meth-
ylation of these genes in astrocytomas [13, 25].
To date, the only gene for which methylation of its pro-
moter has been considered quite important in astrocytoma
tumorigenesis is MGMT. Nakamura et al. [6] reported an
association between MGMT methylation-related silencing
and an increase of GC→AT mutations in the TP53 gene
in high-grade astrocytomas. They also found an association
between MGMT hypermethylation and secondary glioblas-
toma phenotype. In spite of the fact that we do not find
a significant association, our results are rather similar to
those of Nakamura et al., as we found MGMT promoter hy-
permethylation in 15% primary glioblastomas, 50% second-
ary glioblastomas (2 of 4 samples analyzed), and 33% low-
grade diﬀuse astrocytomas. In this case, the discrepancy with
Nakamura et al. may be due to the diﬀerent sample size (we
analyzed a total number of 40 adult astrocytomas, while 106
astrocytomas were studied by Nakamura et al.). We could
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Figure 3: RASSF1A (a) and MGMT (b) methylation frequencies in primary and secondary adult glioblastomas. Horizontal axis: primary
and secondary glioblastoma; vertical axis: number of cases studied. Black boxes: methylated cases; white boxes: unmethylated cases.
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Figure 4: Expression of p14ARF, p16INK4A, MGMT, and RASSF1A in astrocytoma cell lines determined by RT-PCR. PCR products were
visualized in a 2% agarose gel stained with 0.5 μg/mL ethidium bromide. m: molecular weight marker: 1 Kb Plus DNA ladder; 1: U87MG; 2:
A172; 3: H4; 4: GOS3; 5: SW1783; 6: SW1088; 7: CCF-STTG1; 8: MOG-G-CCM; 9: T98G; 10: LN 405; 11: SK-N-Be(2) (neuroblastoma); N:
peripheral blood lymphocytes; 12: genomic DNA; 13: water. Cell lines A172 and H4 were not subjected to the methylation study. A fragment
of the transferrin receptor gene (TFR) was reverse-transcribed as an internal control.
also detect one case of pediatric high-grade astrocytoma with
MGMT hypermethylation, representing 17% of cases ana-
lyzed (6 cases).
RASSF1A showed the highest methylation frequency in
all grades of astrocytoma studied (33% of high-grade (8
GBM and 2 AIII) and 40% of low-grade adult astrocyto-
mas were methylated). Moreover, RASSF1A hypermethyla-
tion significantly associated to secondary glioblastoma phe-
notype, as 4 of 5, secondary glioblastomas, suﬀered hyper-
methylation on its promoter, while only 4 of 19 primary
glioblastomas did so (P = 0.028, Fisher’s exact test). Recently,
RASSF1A promoter methylation has been revealed as a
frequent epigenetic alteration in high-grade astrocytomas
[26, 27]. However, those authors do not specify any clinical
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data of their tumors, so they cannot confirm whether methy-
lation of this gene is associated to primary or secondary
glioblastoma.
RASSF1A was also the most frequently altered gene in
pediatric high-grade astrocytomas, as 4 of 9 cases presented
methylation of this gene; however, not all pediatric samples
could be evaluated for methylation in the five genes, as DNA
extracted from archival material is of worse quality than
DNA from frozen samples.
Recent reports have described frequent RASSF1A hyper-
methylation in pediatric tumors as medulloblastoma, neu-
roblastoma, and Wilms’ tumor [5]. Wong et al. [28] pro-
posed that RASSF1A promoter hypermethylation could be
one of the first steps in pediatric tumorigenesis. However, it
is still unclear whether RASSF1A inactivation is an early step
in the etiology of embryonic tumors, or whether methylation
of its promoter is a secondary eﬀect of a disregulated cell pro-
liferation, which can confer selective advantage to the can-
cer cell. Recently, this gene has been found methylated in
nontumorigenic tissues from normal population, in asso-
ciation to aging [29]. In this way, Li et al. [30] found an
association between N33 and ER methylation in older glio-
blastoma patients, but not in younger patients; both these
genes are more often methylated in normal older individuals
than in younger ones. In spite of this, authors generally agree
on the selective advantage that RASSF1A inactivation confers
to cancer cells, as well as on growth suppression in breast,
prostate, and lung cancer cells through RASSF1A expression
[31, 32].
5. Methylation and Expression in Cell Lines
We could detect methylation in cell lines in much higher fre-
quency than in primary tumors; however, the methylation
profile of the cell lines correlated with the profile in primary
tumors. A higher frequency of tumor suppressor gene pro-
moter hypermethylation in cell lines than in primary tumors
has also been reported previously [33]; this can be due to the
selective growth advantage thatmethylation-related silencing
of tumor-suppressor genes confers to cancer cells, which
can favor clonal selection of cells with aberrant methylation
patterns in successive subcultures.
In our hands, only GOS3 and MOG-G-CCM cell lines
were hypermethylated for PTEN. However, Baeza et al. [23],
who also studied PTENmethylation in astrocytoma cell lines,
found methylation of this gene both in U87 MG and T98G
cells, which were free of methylation in our study. They used
the same set of primers than us, but maybe a higher number
of passages in their cell lines that could have promoted PTEN
methylation due to successive cell replications. Like us, they
did not find PTEN hypermethylation in U251 cells.
RASSF1A was the only gene for which we could see a
good correlation between promoter hypermethylation and
reduction or lack of expression. All astrocytoma cell lines
were methylated for RASSF1A, and none of them expressed
the gene (only SW1088 and LN405 cells showed a faint signal
of expression). On the contrary, in the case of PTEN, we
could not see a reduction of mRNA expression in GOS3
and MOG-G-CCM cells, which had previously shown to
be hypermethylated for this gene; however, they both had
just one methylated allele, the other one remaining free of
methylation, which might be enough to maintain normal
PTEN expression levels.
SW1783, MOG-G-CCM, and LN405 cells expressed the
p14ARF and p16INK4A genes, while U87MG, GOS3, SW1088,
and T98G did not. All cell lines that expressed these genes
did not show any detectable methylation signal. U87MG
and SW1088 cells did not produce a band for p14ARF and
p16INK4A MSP; this might be due to a big homozygous
deletion that aﬀected their promoter. Other mechanisms
diﬀerent from methylation, like homozygous deletion, can
also be responsible of p14ARF silencing in U87 MG and
SW1088 cells [34]; however, this possibility has not been
studied. We cannot find an explanation for the expression of
p16INK4A inMOG-G-CCMcells, when theMSP approach did
not give any interpretable result: maybe MSP could not work
as well as in other experiments, or a mutation in the priming
site, that did not aﬀect gene expression, was the cause of data
misinterpretation after MSP.
In the case of MGMT, although 7 cell lines showed
methylated or hemimethylated alleles, only three of them
lacked expression, while MOG-G-CCM and T98G retained
the MGMT transcript (expression was not evaluated in U118
and U251 cell lines).
6. Conclusion
Our results suggest the existence of mechanisms of inacti-
vation diﬀerent from methylation for p14ARF and p16INK4A
genes, while oﬀer doubts about the direct cause-eﬀect
relationship between promoter methylation and lack of
expression of PTEN and MGMT in astrocytoma cell lines.
This lack of correlation between PTEN hypermethylation
and lack of expression has partially been described by Baeza
et al. [23] by immunohistochemistry in primary human
astrocytomas. However, RASSF1A might be a main target
of methylation-related inactivation in human astrocytoma.
Methylation of RASSF1A might be a diagnosis marker for
secondary glioblastomas and for pediatric astrocytomas.
Being a Ras eﬀector that mediates Ras apoptotic response,
RASSF1A methylation can be an alternative mechanism of
the Ras/MAPK/ERC pathway alteration in those tumors with
intact Ras.
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